Patricia A. Steigerwald, MS, RN has been promoted to vice president, Global Late Phase, Kendle. In this role she will provide executive leadership to drive continued growth of the company’s Late Phase brand globally, with a focus on the design and conduct of Phase IIIb/IV trials, health economics and outcomes research and product/disease registries.

Ms. Steigerwald was most recently senior director, Late Phase and has more than 20 years of CRO and clinical experience. Prior to joining the company she spent seven years with a leading CRO in a variety of positions in the late stage trials division, serving most recently as executive director, where she was responsible for the strategic direction and the development of goals, systems and procedures to ensure timely delivery of Phase IIIB/IV trials. Her experience also includes providing strategic guidance and oversight in the conduct of one of the world’s largest global cardiovascular medical outcomes trials ever conducted.

“Phase IIIb/IV continues to be an area of significant customer need, with the global outsourcing market estimated to reach $4.7 to $4.8 billion by 2010,” said Kendle chairman and chief executive officer, Dr. Candace Kendle, Pharm.D. “Pat’s expertise in the strategic and operational design and execution of large clinical endpoint trials will further position Kendle to capitalize on this exciting and growing marketing opportunity in the global late phase market.”